Nabriva Therapeutics (NBRV) Stock Forecast, Price Target & Predictions


OverviewOwnershipChart

NBRV Stock Forecast


Nabriva Therapeutics stock forecast is as follows: an average price target of $1.00 (represents a 58.73% upside from NBRV’s last price of $0.63) and

NBRV Price Target


Nabriva Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 06, 2023Carl ByrnesNorthland Securities$1.00$1.33-24.81%58.73%
Row per page
Go to

The latest Nabriva Therapeutics stock forecast, released on Jan 06, 2023 by Carl Byrnes from Northland Securities, set a price target of $1.00, which represents a -24.81% decrease from the stock price at the time of the forecast ($1.33), and a 58.73% increase from NBRV last price ($0.63).

Nabriva Therapeutics Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.63$0.63$0.63
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Nabriva Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nabriva Therapeutics's last price of $0.63. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Nabriva Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
EVOKEvoke Pharma$4.37$18.00311.90%Buy
TRVNTrevena$1.68$3.50108.33%-
NBRVNabriva Therapeutics$1.42$1.00-29.58%-

NBRV Forecast FAQ


Will Nabriva Therapeutics stock go up soon?

According to Wall Street analysts' prediction for NBRV stock, the company can go up by 58.73% (from the last price of $0.63 to the average price target of $1), up by 58.73% based on the highest stock price target, and up by 58.73% based on the lowest stock price target.

Can Nabriva Therapeutics stock reach $1?

NBRV's average twelve months analyst stock price target of $1 does not support the claim that Nabriva Therapeutics can reach $1 in the near future.